Menu
Search
|

Menu

Close
X

Novo Nordisk A/S NOVOB.CO (Copenhagen Stock Exchange)

313.45 DKK
+8.25 (+2.70%)
As of Feb 16
chart
Previous Close 305.20
Open 309.50
Volume 3,014,036
3m Avg Volume 3,083,445
Today’s High 314.65
Today’s Low 306.85
52 Week High 354.80
52 Week Low 230.20
Shares Outstanding (mil) 1,962.56
Market Capitalization (mil) 615,165.69
Forward P/E 20.38
Dividend (Yield %) 4.85 ( 2.50 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.48 Mean rating from 31 analysts

KEY STATS

Revenue (mm, DKK)
FY17
111,696
FY16
111,780
FY15
107,927
EPS (DKK)
FY17
15.377
FY16
14.960
FY15
13.518
*Note: Units in Millions of Danish Krone
**Note: Units in Danish Krone

KEY RATIOS

Price to Earnings (TTM)
vs sector
20.38
34.43
Price to Sales (TTM)
vs sector
5.51
8.57
Price to Book (MRQ)
vs sector
15.38
5.14
Price to Cash Flow (TTM)
vs sector
14.89
25.75
Total Debt to Equity (MRQ)
vs sector
3.40
15.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.85
Return on Investment (TTM)
vs sector
72.35
13.54
Return on Equity (TTM)
vs sector
80.20
14.80

EXECUTIVE LEADERSHIP

Goran Ando
Chairman of the Board, Since 2013
Salary: --
Bonus: --
Lars Fruergaard Joergensen
President, Chief Executive Officer, Since 2017
Salary: kr.8,500,000.00
Bonus: kr.9,200,000.00
Jeppe Christiansen
Vice Chairman of the Board, Since 2013
Salary: --
Bonus: --
Jesper Brandgaard
Chief Financial Officer, Executive Vice President, Head of Biopharm, Since 2017
Salary: kr.6,300,000.00
Bonus: kr.4,600,000.00
Maziar Doustdar
Executive Vice President, International Operations, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Novo Alle
BAGSVAERD     2880

Phone: +4544.448888

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

SPONSORED STORIES